Railway Pension Investments Ltd Increases Position in IDEXX Laboratories, Inc. $IDXX

Railway Pension Investments Ltd boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 92.1% during the 3rd quarter, Holdings Channel reports. The firm owned 296,530 shares of the company’s stock after buying an additional 142,200 shares during the quarter. IDEXX Laboratories makes up about 2.6% of Railway Pension Investments Ltd’s holdings, making the stock its 8th biggest position. Railway Pension Investments Ltd’s holdings in IDEXX Laboratories were worth $189,450,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. STF Management LP increased its stake in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after acquiring an additional 16 shares during the last quarter. Clearstead Trust LLC increased its position in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its position in IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after buying an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. boosted its stake in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after buying an additional 18 shares during the period. Finally, Private Trust Co. NA raised its stake in shares of IDEXX Laboratories by 9.4% in the third quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after acquiring an additional 18 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IDXX. Barclays assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 price target for the company. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Monday, December 29th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Finally, UBS Group upped their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Trading Down 1.0%

Shares of NASDAQ IDXX opened at $669.99 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The firm has a market cap of $53.50 billion, a PE ratio of 53.13, a price-to-earnings-growth ratio of 3.58 and a beta of 1.67. The business has a fifty day simple moving average of $699.69 and a two-hundred day simple moving average of $638.31. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.